AMGN Amgen

XNGS Up Alert

Health Care

· How we analyze

About the company

Amgen is a biotechnology company from California. It develops medicines for bone loss, cancer, cardiovascular disease, inflammation and rare diseases, such as Prolia, Repatha and Enbrel. Rare diseases were added through the acquisition of Horizon. As of Oct 13, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Thousand Oaks, USA

The company researches, develops, manufactures and delivers medicines and operates in a single segment for human therapeutics. Its products include Prolia for osteoporosis, Repatha for lipid disorders and Otezla for psoriasis. In the US market, almost all deliveries go to pharmaceutical wholesalers, including McKesson, Cencora and Cardinal Health. Outside that market, sales go mainly to healthcare providers or wholesalers, depending on the country. In the Asia-Pacific region the group also markets products with partners such as Astellas and Takeda. In January 2026 the FDA asked the subsidiary ChemoCentryx to voluntarily withdraw TAVNEOS from the US market, which the group declined.

Automatically summarized from SEC annual report (10-K, filed Feb 13, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Amgen

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +1.2%
  • 7 days +4.6%
  • 30 days +7.2%
  • 1 year +52.4%
Day range (last trading day)
−1.2%Price at 50% of the range+1.2%
52-week range
−35.2%Price at 96% of the range+1.4%
Distance from the all-time high
−1.4%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NASDAQ:AMGN

Fundamental analysis

Amgen · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 13, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+7.6% per year), more slowly than the sector median.
  • Light yellow: Net income (total) grew over 5 years (+1.2% per year), more slowly than the sector median; per share +2.9% per year.
  • Light green: Net margin 21.0%, above the sector median (12.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.
  • Light yellow: High payout ratio (68% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 23.0B USD · Net income 7.7B USD · Net margin 33.6%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 22.8B USD · Net income 2.0B USD · Net margin 8.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 23.7B USD · Net income 8.4B USD · Net margin 35.3%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 23.4B USD · Net income 7.8B USD · Net margin 33.6%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 25.4B USD · Net income 7.3B USD · Net margin 28.6%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 26.0B USD · Net income 5.9B USD · Net margin 22.7%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 26.3B USD · Net income 6.6B USD · Net margin 24.9%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 28.2B USD · Net income 6.7B USD · Net margin 23.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 33.4B USD · Net income 4.1B USD · Net margin 12.2%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 36.8B USD · Net income 7.7B USD · Net margin 21.0%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 36.8B USD · Net income 7.7B USD · Net margin 21.0%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+7.6% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 7.6% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+1.2% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +2.9% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 1.2% per year on average, but more slowly than the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

21.0% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 20.98 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 28.6%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

4.90 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 4.90 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

68% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.68 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
36.8B USD
Revenue vs. prior year
+10.0%
Net income (FY)
7.7B USD
Net income vs. prior year
+88.5%
EPS (FY)
14.23 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
–
Fiscal year to Dec 31, 2025 · 10-K filed Feb 13, 2026 · Balance sheet Jun 30, 2026 (filed Aug 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 36.8B7.7B 21.0% 14.23 9.66 68%
2024Dec 31, 2024 33.4B4.1B 12.2% 7.56 9.13 121%
2023Dec 31, 2023 28.2B6.7B 23.8% 12.49 8.64 69%
2022Dec 31, 2022 26.3B6.6B 24.9% 12.11 7.95 66%
2021Dec 31, 2021 26.0B5.9B 22.7% 10.28 7.22 70%
2020Dec 31, 2020 25.4B7.3B 28.6% 12.31 6.56 53%
2019Dec 31, 2019 23.4B7.8B 33.6% 12.88 5.95 46%
2018Dec 31, 2018 23.7B8.4B 35.3% 12.62 5.41 43%
2017Dec 31, 2017 22.8B2.0B 8.7% 2.69 4.77 177%
2016Dec 31, 2016 23.0B7.7B 33.6% 10.24 4.15 41%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 10.1B2.4B 23.6% 4.37 – –
Q1/26Mar 31, 2026 8.6B1.8B 21.1% 3.34 2.52 75%
Q4/25*Dec 31, 2025 9.9B1.3B 13.5% – 2.38 –
Q3/25Sep 30, 2025 9.6B3.2B 33.7% 5.93 2.38 40%
Q2/25Jun 30, 2025 9.2B1.4B 15.6% 2.65 2.38 90%
Q1/25Mar 31, 2025 8.1B1.7B 21.2% 3.20 2.38 74%
Q4/24*Dec 31, 2024 9.1B627.0M 6.9% – 2.38 –
Q3/24Sep 30, 2024 8.5B2.8B 33.3% 5.22 2.25 43%
Q2/24Jun 30, 2024 8.4B746.0M 8.9% 1.38 2.25 163%
Q1/24Mar 31, 2024 7.4B−113.0M −1.5% −0.21 2.25 –
Q4/23*Dec 31, 2023 8.2B767.0M 9.4% – 2.25 –
Q3/23Sep 30, 2023 6.9B1.7B 25.1% 3.22 2.13 66%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $4.1M3 people −$4.1M
6 months $00 people $4.5M3 people −$4.5M
12 months $00 people $29.3M6 people −$29.3M

Latest transactions

  • Aug 13, 2026 Khosla Rachna Officer Open-market sale 1,252 shares · $521.4K · SEC
  • Aug 11, 2026 Khosla Rachna Officer Open-market sale 2,000 shares · $825.1K · SEC
  • Aug 6, 2026 Miller Derek Officer Open-market sale 1,821 shares · $733.0K · SEC
  • Aug 6, 2026 Miller Derek Officer Open-market sale 2,069 shares · $832.9K · SEC
  • Aug 6, 2026 Grygiel Nancy A. Officer Open-market sale 1,000 shares · $402.2K · SEC
  • Aug 6, 2026 Grygiel Nancy A. Officer Open-market sale 1,970 shares · $792.3K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +80

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)27.8
Rel. strength 60 d+12.7%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on AMGN yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: AMGN

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close